NewAmsterdam Pharma Company N.V. announced full year 2025 financial results, reporting $728.9 million in cash, cash equivalents and marketable securities as of December 31, 2025, revenue of $22.5 million, and net loss of $203.8 million. The company provided updates on obicetrapib regulatory approvals expected in 2H26 and ongoing Phase 3 trials.
Key takeaways
Cash, cash equivalents and marketable securities of $728.9 million at December 31, 2025, down from $834.2 million at December 31, 2024
Revenue of $22.5 million for year ended December 31, 2025, compared to $45.6 million in 2024
Net loss of $203.8 million for year ended December 31, 2025, compared to $241.6 million in 2024
R&D expenses $141.8 million in 2025, down from $151.4 million in 2024
SG&A expenses $106.4 million in 2025, up from $70.4 million in 2024
Approval decisions for obicetrapib and obicetrapib/ezetimibe FDC expected from EMA, UK and Switzerland regulators in 2H26
Topline data from RUBENS Phase 3 trial expected by year-end 2026